Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of concomitant COVID-19 inactivated vaccine with quadrivalent influenza vaccine or 23-valent pneumococcal polysaccharide vaccine
ChiCTR2100046174Phase 4Suspended
- Sponsor
- Shanghai Municipal Center for Disease Control and Prevention
- Start
- May 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in coronavirus disease 2019 (COVID-19), influenza and pneumococcal disease (3 arms), sponsored by Shanghai Municipal Center for Disease Control and Prevention. Primary endpoints: Seroconversion rate, Antibody positive rate and 1 more. Started May 2021; status: suspended.
02
Drugs
quadrivalent influenza vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)influenzapneumococcal disease
Beyond the preview
Go deeper on ChiCTR2100046174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046174.